IQVIA Holdings Inc. (NYSE:IQV) Stock Holdings Lessened by California Public Employees Retirement System

California Public Employees Retirement System trimmed its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 345,955 shares of the medical research company's stock after selling 11,672 shares during the period. California Public Employees Retirement System owned approximately 0.19% of IQVIA worth $80,047,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. CWM LLC grew its stake in IQVIA by 5.5% in the fourth quarter. CWM LLC now owns 3,980 shares of the medical research company's stock valued at $921,000 after acquiring an additional 207 shares during the period. Signaturefd LLC raised its holdings in IQVIA by 13.0% during the 4th quarter. Signaturefd LLC now owns 2,492 shares of the medical research company's stock worth $577,000 after buying an additional 287 shares during the period. Carmel Capital Partners LLC boosted its holdings in shares of IQVIA by 1.0% in the fourth quarter. Carmel Capital Partners LLC now owns 6,610 shares of the medical research company's stock valued at $1,529,000 after buying an additional 67 shares during the period. abrdn plc increased its position in shares of IQVIA by 138.3% during the fourth quarter. abrdn plc now owns 108,151 shares of the medical research company's stock worth $25,024,000 after acquiring an additional 62,776 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its position in IQVIA by 0.5% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 119,262 shares of the medical research company's stock valued at $27,595,000 after acquiring an additional 600 shares in the last quarter. Institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on IQV. BTIG Research assumed coverage on IQVIA in a research note on Tuesday, February 13th. They issued a "buy" rating and a $285.00 price target on the stock. UBS Group lifted their price objective on shares of IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, February 15th. Robert W. Baird lifted their target price on IQVIA from $226.00 to $251.00 and gave the company a "neutral" rating in a research report on Thursday, February 15th. SVB Leerink began coverage on IQVIA in a research note on Monday, February 26th. They issued an "outperform" rating and a $290.00 price target for the company. Finally, Truist Financial boosted their price target on IQVIA from $286.00 to $297.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $256.80.

Insider Activity at IQVIA

In related news, insider Ari Bousbib sold 31,678 shares of the business's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company's stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Eric Sherbet sold 1,000 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the transaction, the insider now owns 20,836 shares of the company's stock, valued at approximately $5,031,894. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,285 shares of company stock worth $10,331,003. Company insiders own 1.60% of the company's stock.

IQVIA Stock Performance

Shares of NYSE IQV traded down $6.86 during trading hours on Thursday, reaching $233.98. 1,061,417 shares of the stock were exchanged, compared to its average volume of 973,451. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The stock's fifty day simple moving average is $245.50 and its 200 day simple moving average is $222.69. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm has a market capitalization of $42.47 billion, a price-to-earnings ratio of 33.04, a P/E/G ratio of 2.31 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The company had revenue of $3.87 billion during the quarter, compared to analysts' expectations of $3.80 billion. During the same quarter in the previous year, the business posted $2.54 earnings per share. IQVIA's quarterly revenue was up 3.5% on a year-over-year basis. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.